3 / 16
Page 18
Notes:
conferenceseries
.com
Volume 8, Issue 10 (Suppl)
J Diabetes Metab
ISSN: 2155-6156 JDM, an open access journal
Herbal Diabetes 2017
November 02-04, 2017
November 02-04, 2017 Bangkok, Thailand
23
rd
International Conference on
Herbal and Alternative Remedies for
Diabetes and Endocrine Disorders
Controlled clinical study of anAyurvedic anti-diabetic formulation BGR-34 tablets for its efficacy and
safety in patients with diabetes mellitus
A Rathi
1
, B P Gupta
2
, A Kumar
2
, B P S Tomar
2
, I Sharma
1
, N Kohli
3
, S Sharma
1
and A K Sharma
1
1
Aimil Pharmaceuticals Ltd., India
2
Aggarwal Dharmarth Hospital, India
3
Aimil Healthcare and Research Centre Ltd., India
Introduction & Aim:
According to International Diabetes Federation, 415 million adults were living with diabetes in 2015 and
this number is expected to increase to around 642 million by 2040. The Scientists of India, Council for Scientific & Industrial
Research (CSIR) has realized the alarming rise in incidence of diabetes and developed scientifically validated, anti-diabetic
ayurvedic drug to prevent and treat Diabetes mellitus type-2. CSIR, has been ranked 12
th
in the world among the government
institutions. The drug has been developed jointly by scientist of National Botanical Research Institute (NBRI) and Central
Institute for Medicinal & Aromatic Plants (CIMAP), the Lucknow, India-based research units of CSIR. Scientists of NBRI and
CIMAP made an in-depth study on 500 anti-diabetic herbs from ancient literature of Indian System of Medicine Ayurveda
(
Caraka Samhita, Sushruta Samhita, Astanga Hridaya and Bhavprakash
) and finally identified the six herbs (
Berberis aristata,
Tinospora cordifolia, Pterocarpus marsupium, Gymnema sylvestre, Rubia cordifoila and Trigonella foenumgraecum
). Pre-clinical
studies conducted by CSIR on BGR-34 produced encouraging results in diabetes induced experimental subjects (unpublished
data CSIR). Encouraged by the preclinical outcome, CSIR moved to investigate the active components from BGR-34 and we
moved to test its clinical efficacy, with an aim to ensure the scientific validity, efficacy and safety of BGR-34 on blood glucose
regulation with type-2 diabetes mellitus based on clinical studies.
Methodology:
A double blind placebo controlled clinical study of BGR-34 in patients with type-2 DM was approved by the
independent human ethics committee of Aggarwal Dharmarth Hospital, New Delhi, India.
Findings:
BGR-34, showed promising result with respect to glycemic parameters in patient with type-2 diabetes with significant
reduction in fasting blood sugar by 34.3%, post prandial blood sugar by 35.5% and glycosylated hemoglobin by 20.31% as
compared to placebo group showing reduction by 13.2%, 10.9% and 10.87%, respectively. The trial has also been registered to
CTRI, India.
Conclusion & Significance:
BGR 34 has been investigated to contain a number of active biomolecule molecules including
the compound berberine (
Berberis aristata
), a natural dipeptidyl peptidase IV (DPP-4) inhibitor, that act by increasing
endogenous GLP-1 and GIP concentrations. Via this mechanism, insulin secretion is glucose-dependently stimulated and
glucagon secretion inhibited.
Biography
Anshu Rathi is working as a Team Lead at Aimil Pharmaceuticals (India)Ltd. Her wide range of publications in various national and international journals.
anshu.rathi@aimilpharmaceuticals.comA Rathi et al., J Diabetes Metab 2017, 8:10 (Suppl)
DOI: 10.4172/2155-6156-C1-072